Medline Inc. announced the pricing of a secondary offering of 60,000,000 shares of its Class A common stock on November 17, 2026. The shares are being sold by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC, GIC Private Limited, and a wholly owned subsidiary of the Abu Dhabi Investment Authority. The shares were priced to the public at $35.50 per share. Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan are serving as global coordinators and joint bookrunning managers for the transaction.

The offering is expected to close on November 23, 2026, subject to customary closing conditions. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 9,000,000 shares. Medline is not selling any shares in the offering and will not receive any proceeds from the sale. The transaction is expected to result in net proceeds of approximately $2.1 billion to the selling stockholders, excluding the potential additional shares from the underwriters' option.

In conjunction with the offering, Medline and Medline Holdings, LP entered into a share and unit repurchase agreement. The company and Medline Holdings agreed to repurchase an aggregate of $200 million of Class A common stock and limited partnership interests (Common Units) directly from the selling stockholders in a private, non-underwritten transaction. The repurchase price per equity interest is equal to the price paid by the underwriters in the offering.

Under the terms of the repurchase agreement, if Common Units are repurchased from a selling stockholder, that stockholder will transfer an equivalent number of shares of Medline’s Class B common stock to the company for no additional consideration. These Class B shares will be cancelled and retired upon closing. The repurchase is expected to close concurrently with the offering and is conditioned upon the closing of the offering. The repurchase has been approved by the Audit Committee of Medline’s Board of Directors and will count toward the company’s previously announced share repurchase program.